N-乙基-N-甲基-1-哌嗪甲酰胺 | 657427-50-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: N-乙基-N-甲基-1-哌嗪甲酰胺
• 英文名称: piperazine-1-carboxylic acid ethyl-methyl-amide
• 英文别名: N-Ethyl-N-methylpiperazine-1-carboxamide
• CAS: 657427-50-4
• 化学式: C₈H₁₇N₃O
• 分子量: 171.242
• InChiKey: ZFYGGVBLZUTPCF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  35.6
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-乙基-N-甲基-1-哌嗪甲酰胺 、 3-chloromethyl-5-m-tolyl-[1,2,4]oxadiazole 在 potassium carbonate 作用下， 以 乙腈 为溶剂， 以13%的产率得到4-[1-(5-m-tolyl-[1,2,4]oxadiazol-3-yl)-ethyl]-piperazine-1-carboxylic acid ethyl-methyl-amide
  参考文献：
  名称：

  [EN] OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
  [FR] NOUVEAUX COMPOSES

  摘要：

  公开号：

  WO2004014370A3
• 作为产物：
  描述：

  tert-butyl 4-(1H-imidazole-1-carbonyl)piperazine-1-carboxylate 在 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 1.0h， 生成 N-乙基-N-甲基-1-哌嗪甲酰胺
  参考文献：
  名称：

  [EN] OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
  [FR] NOUVEAUX COMPOSES

  摘要：

  公开号：

  WO2004014370A3

文献信息

• New compounds
  申请人：AstraZeneca AB and NPS Pharmaceuticals, Inc.

  公开号：US20040132726A1

  公开（公告）日：2004-07-08

  The present invention relates to new compounds of formula I, 1 wherein P, Q, X 1 , X 2 , X 3 , X 4 , X 4 , R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.

  本发明涉及公式I的新化合物，其中P、Q、X1、X2、X3、X4、X4、R、R1、R2、R3、R4、R5、R6、R7、m、n、o、p和q如权利要求书1至12中的任一项所定义，以及其制备过程和制备其中的新中间体，含有该化合物的药物配方和在治疗中使用该化合物的用途。
• OXADIAZOLES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5
  申请人：AstraZeneca AB

  公开号：EP1536790A2

  公开（公告）日：2005-06-08
• 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS
  申请人：IDEAYA BIOSCIENCES, INC.

  公开号：US20220389003A1

  公开（公告）日：2022-12-08

  Provided herein are compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , Ar, X 1 , X 2 , and ring B have the meanings as provided herein. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors.
• [EN] NEW COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA AB

  公开号：WO2004014370A2

  公开（公告）日：2004-02-19

  The present invention relates to new compounds of formula (I), wherein P, Q, X1, X2, X3, X4, R, R1, R2, R3, R4, R5, R6, R7, m, n, o, p and q are defined as in any one of claims 1 to 12, a process for their preparation and new intermediates prepared therein, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy. It has been found that the compounds according to the present invention, or salts therof, exhibit a high degree of potency and selectivity for individual metabotropic glutamate receptor (mGluR) subtypes. In particular there are compounds according to the present invention that are potent and selective for the mGluR Group I receptor and more particularly for mGluR5. Thus, it is expected that the compounds of the invention are well suited for the prevention and/or treatment of mGluR5 receptor-mediated disorders such as acute and chronic neurological and psychiatric disorders and chronic and acute pain disorders.
• [EN] 4-SUBSTITUTED INDOLE AND INDAZOLE SULFONAMIDO DERIVATIVES AS PARG INHIBITORS<br/>[FR] DÉRIVÉS DE SULFONAMIDO D'INDOLE ET D'INDAZOLE SUBSTITUÉS EN POSITION 4 EN TANT QU'INHIBITEURS DE PARG
  申请人：IDEAYA BIOSCIENCES INC

  公开号：WO2021055744A1

  公开（公告）日：2021-03-25

  Provided herein are compounds having the formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, Ar, X1, X2, and ring B have the meanings as provided herein. The provided compounds are useful Poly ADP-ribose glycohydrolase (PARG) inhibitors.